Ranexa
$ 49,00 – $ 310,00Price range: $ 49,00 through $ 310,00
Ranol SR
$ 44,00 – $ 132,00Price range: $ 44,00 through $ 132,00
Ranitidine
$ 45,00 – $ 136,00Price range: $ 45,00 through $ 136,00
Ranitidine is a reliable H2-receptor antagonist designed to manage various acid-related digestive conditions. It works by decreasing the amount of acid produced in the stomach to provide lasting comfort and relief. This medication is primarily used to treat and prevent symptoms of heartburn, acid indigestion, and sour stomach. Additionally, it is effective in the healing and prevention of ulcers in both the stomach and the intestines. Regular use helps manage gastroesophageal reflux disease (GERD) to improve overall digestive health and daily comfort.
Active substance: ranitidine
SKU:
Ranitidine
Category: Gastrointestinal Tract
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM
Each dosage option has its own packaging choices.
Description
Ranitidine belongs to a group of medicines called histamine-2 (H2) receptor antagonists. It was historically formulated to suppress gastric acid production by competitively inhibiting histamine action at the H2 receptors of parietal cells in the stomach lining.
In the United States, ranitidine products were previously dispensed in accordance with applicable federal and state regulations across prescription and non-prescription categories. In April 2020, the U.S. Food and Drug Administration (FDA) requested the market withdrawal of all ranitidine products due to findings of N-nitrosodimethylamine (NDMA) impurities, requiring patients to consult healthcare providers for alternative acid-suppressive therapies.
General Drug Profile and Clinical Overview
Key Information Summary
| Property | Details |
|---|---|
| Active ingredient | Ranitidine hydrochloride |
| Therapeutic class | Histamine H2-receptor antagonist |
| Dosage form | Oral tablet, oral solution, injectable solution (historical) |
| Route of administration | Oral, intravenous, intramuscular |
| Mechanism of action | Competitive inhibition of H2 receptors on parietal cells |
| Storage requirements | Controlled room temperature 20°C to 25°C (68°F to 77°F) |
Pharmacology, Indications, and Dosing
How the drug works: Ranitidine functions as a selective, competitive antagonist of histamine at the H2-receptor sites located on the basolateral membrane of gastric parietal cells. By interfering with histamine binding, the drug inhibits both basal and stimulated gastric acid secretion. It diminishes the total volume of gastric juice produced as well as its hydrogen ion concentration. Ranitidine does not directly alter pepsin secretion, though total pepsin output decreases proportionally with reduced gastric volume. Furthermore, it does not significantly affect lower esophageal sphincter pressure or gastric emptying time under standard therapeutic conditions.
What it’s used for: Ranitidine gained FDA approval for the treatment and maintenance of duodenal ulcers, active benign gastric ulcers, and gastroesophageal reflux disease (GERD), including erosive esophagitis. It was also indicated for pathologic hypersecretory conditions, such as Zollinger-Ellison syndrome and systemic mastocytosis. Off-label uses historically documented in medical literature included the prevention of stress-induced mucosal damage in critically ill patients and pre-anesthetic administration to reduce the risk of acid aspiration during surgical procedures; such non-labeled uses require distinct clinical evaluation by a licensed prescriber.
Dosing schedule: In clinical practice prior to market withdrawal, ranitidine oral dosages were individualized based on the specific medical condition and renal clearance. For active duodenal or gastric ulcers, a standard adult regimen was 150 mg twice daily or 300 mg once daily at bedtime. Maintenance therapy for healed ulcers generally involved 150 mg taken at bedtime. For erosive GERD, standard regimens frequently utilized 150 mg twice daily or 150 mg four times daily depending on severity. Patients with severe renal impairment (creatinine clearance under 50 mL/min) required dose reductions, often to 150 mg every 24 hours, to prevent drug accumulation.
How it’s absorbed and eliminated: Following oral administration, ranitidine exhibits an absolute bioavailability of approximately 50% due to first-pass hepatic metabolism. Peak plasma concentrations are typically reached within 2 to 3 hours post-ingestion. The drug is broadly distributed throughout body tissues, with a plasma protein binding rate of approximately 15%. The elimination half-life ranges from 2.5 to 3 hours in individuals with normal renal function, but extends significantly in patients with renal insufficiency. Ranitidine is excreted primarily via the kidneys through active tubular secretion and glomerular filtration, with a minor portion metabolized in the liver to ranitidine N-oxide, S-oxide, and desmethylranitidine.
Clinical Safety and Risk Profile
Safety, Interactions, and Special Populations
Compatibility with other medicines: Ranitidine has a substantially lower affinity for cytochrome P450 enzyme systems compared to cimetidine, minimizing its potential to alter the hepatic metabolism of co-administered drugs. However, by elevating gastric pH, ranitidine can decrease the gastrointestinal absorption of drugs requiring an acidic environment, such as ketoconazole, itraconazole, and certain antiretroviral agents like atazanavir. Concurrent use with triamterene may reduce renal clearance of the diuretic. Clinical monitoring is advised when co-administered with warfarin, as isolated reports suggest altered prothrombin time, although systematic metabolic interactions remain minimal.
Adverse reactions: Ranitidine is generally well tolerated, but adverse effects can occur across multiple organ systems. Common mild reactions include headache, drowsiness, dizziness, constipation, or diarrhea. Less frequent central nervous system effects–such as reversible confusion, agitation, depression, and hallucinations–have been documented, predominantly in elderly patients or individuals with severe renal or hepatic dysfunction. Rare hematologic abnormalities include leukopenia, granulocytopenia, and thrombocytopenia. Mild, reversible elevations in serum transaminases and serum creatinine may also occur during therapy.
What to avoid while taking it: Food intake does not significantly interfere with the bioavailability of ranitidine, allowing administration with or without meals. However, concurrent alcohol consumption should be approached with caution. H2-receptor antagonists can potentially inhibit gastric alcohol dehydrogenase, leading to elevated blood alcohol concentrations following ethanol ingestion. Patients are advised to limit alcohol intake during acid-suppressive therapy to avoid gastrointestinal mucosal irritation and unexpected changes in ethanol clearance.
Important precautions: Symptomatic response to ranitidine therapy does not preclude the presence of gastric malignancy; appropriate diagnostic evaluation is recommended prior to initiating long-term treatment. Caution is warranted in patients with hepatic impairment, as ranitidine undergoes partial hepatic metabolism. In patients with severe renal dysfunction, dosage adjustments are mandatory to avoid accumulation and central nervous system toxicity. Additionally, rare reports link ranitidine administration to acute porphyria attacks; use in patients with a history of acute porphyria should be avoided.
If you skip a dose: If a scheduled dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. Patients should not double the dose to make up for a missed tablet. Maintaining a consistent schedule supports stable gastric acid suppression throughout the treatment period.
Storage and expiration: Solid oral dosage forms should be stored at controlled room temperature between 20°C and 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F to 86°F). Protect the medication from light, excessive moisture, and heat. Keep all formulations out of reach of children and dispose of expired or withdrawn products in accordance with local environmental safety guidelines.
Pregnancy, breastfeeding, and other groups: Ranitidine crosses the placenta. Animal reproduction studies have failed to demonstrate risk to the fetus, but adequate, well-controlled studies in pregnant women are limited. Ranitidine is excreted in human milk, often achieving higher concentrations in breastmilk than in maternal plasma; caution is advised when administered to nursing mothers. Pediatric safety and effectiveness have been established for specific age groups using weight-based dosing parameters.
Frequently Asked Questions
What was the primary regulatory reason for the FDA recall of ranitidine products?
The FDA requested the market withdrawal of all ranitidine products after testing confirmed that levels of N-nitrosodimethylamine (NDMA), an environmental impurity classified as a probable human carcinogen, increased over time and at room temperature, potentially exposing consumers to unacceptable impurity levels.
How does ranitidine differ mechanism of action from proton pump inhibitors (PPIs)?
Ranitidine blocks histamine-2 receptors on gastric parietal cells to decrease acid production, whereas proton pump inhibitors (such as omeprazole) directly inhibit the H+/K+ ATPase enzyme system, producing a more potent and prolonged acid suppression.
Can ranitidine cause central nervous system side effects in older adults?
Yes, elderly patients–particularly those with concurrent renal or hepatic impairment–are at higher risk for central nervous system adverse events, including reversible confusion, disorientation, dizziness, and agitation.
Is dosage adjustment necessary for patients with impaired kidney function?
Yes, because ranitidine is primarily cleared by the kidneys, patients with reduced creatinine clearance (below 50 mL/min) require dosage frequency or total daily dose reductions to prevent drug accumulation and potential toxicity.
In accordance with FDA requirements.
Information on this page is for reference and does not replace an assessment by a licensed healthcare professional.
Additional information
| Dosage |
300mg |
|---|---|
| Package |
90 pills ,120 pills ,180 pills ,270 pills ,360 pills |
| Ενεργός Ουσία |
Related products
Ascorbic Acid
$ 58,00 – $ 69,00Price range: $ 58,00 through $ 69,00
Active substance: Ascorbic Acid
More Details
This product has multiple variants. The options may be chosen on the product page
Biaxin
$ 107,00 – $ 427,00Price range: $ 107,00 through $ 427,00
Active substance: Clarithromycin
More Details
This product has multiple variants. The options may be chosen on the product page
Budez CR
$ 23,00 – $ 108,00Price range: $ 23,00 through $ 108,00
Active substance: Budesonide
More Details
This product has multiple variants. The options may be chosen on the product page
Diarex
$ 54,00 – $ 236,00Price range: $ 54,00 through $ 236,00
Active substance: Diarex
More Details
This product has multiple variants. The options may be chosen on the product page
Ditropan
$ 23,00 – $ 262,00Price range: $ 23,00 through $ 262,00
Active substance: Oxybutynin
More Details
This product has multiple variants. The options may be chosen on the product page
Herbolax
$ 50,00 – $ 83,00Price range: $ 50,00 through $ 83,00
Active substance: Chebulic Myrobalan, Trivruth
More Details
This product has multiple variants. The options may be chosen on the product page
Meclizine
$ 47,00 – $ 143,00Price range: $ 47,00 through $ 143,00
Active substance: Meclizine
More Details
This product has multiple variants. The options may be chosen on the product page
Motilium
$ 40,00 – $ 95,00Price range: $ 40,00 through $ 95,00
Active substance: domperidone
More Details
This product has multiple variants. The options may be chosen on the product page
